Inmode Ltd scores 98 for management and 53 for moat. The management score rests on a return on invested capital of 10.4% and a gross margin of 78.5% — figures that describe a business turning capital into profit efficiently. Debt sits at 0.02x equity. The moderate moat and exceptional management are not the same judgement, and the gap between them is where the argument about this business sits.
The price anchors are built on deliberately conservative assumptions. Growth is modelled at 12.4% a year, the rate measured from the filings. The exit multiple assumed is 24.9x. That produces an intrinsic value of $24.45, a 10-CAP price of $14.78 and a payback time price of $20.78, with the value zone set at the highest of the three, $20.78. Today's price of $14.05 sits inside that zone.
A business scoring this well, trading inside its value zone, is the combination the framework exists to find — which is also the reason to check why the market disagrees. A margin of safety score of 87 describes the cushion, not the certainty.
| Price | $14.05 |
| Market cap | $807.6M |
| P/E ratio | 11.4x |
| Return on invested capital | 10.4% |
| Gross margin | 78.5% |
| Debt to equity | 0.02x |
| Free cash flow yield | 8.9% |
| Growth rate used | 12.4% |
| Growth rate measured | 12.0% |
| Exit multiple assumed | 24.9x |
| Company | Moat | Buy price |
| Insulet Corporation (PODD) | 82 | $82.38 |
| Align Technology (ALGN) | 51 | $134.51 |
| Zimmer Biomet (ZBH) | 59 | $91.89 |
| GE HealthCare Technologies (GEHC) | 23 | $23.16 |
Every number above is built on assumptions that can be changed. In Moatly you can move the growth rate, the exit multiple and the margin of safety and watch every figure recalculate, so you are testing your own view of Inmode Ltd rather than accepting ours.